Using migraine medications to treat Meniere's disease
Official title: Treatment of Meniere's Disease With Nortriptyline-Topiramate Stepwise Regimen: A Randomized Double-Blinded Clinical Trial
Run by University of California, Irvine · NCT05582837 · Data updated 2026-11-12
This study is testing whether migraine medications can help people with Meniere's disease feel better by reducing their vertigo, hearing loss, and tinnitus.
Quick facts
| Phase | Phase 4 |
|---|---|
| Study type | Interventional |
| Ages | 25 Years to 85 Years |
| Sex | All |
| Enrollment | 40 (estimated) |
| Sponsor | University of California, Irvine Academic / other |
| Locations | 1 site (Orange, California) |
| Status | Recruiting |
| Started | August 1, 2022 |
| Main results expected | December 30, 2027 |
| Study ends | December 30, 2027 |
| Registry record updated | June 22, 2026 |
| Trial ID | NCT05582837 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults aged 25 to 85 with active or frequent Meniere's disease.
✕Probably not a fit
Patients who have undergone surgery for Meniere's disease or have a history of adverse reactions to the medications being tested may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This clinical trial aims to evaluate the effectiveness of migraine medications in treating Meniere's disease, a chronic condition characterized by vertigo, hearing loss, and tinnitus. The study will last for 8 weeks and involves two treatment arms: one group will receive nortriptyline and topiramate, while the other will receive hydrochlorothiazide and triamterene, with the possibility of placebo. Participants will be randomly assigned to one of the treatment groups and will undergo weekly assessments of their symptoms. The trial is double-blinded to ensure unbiased results.
Why it matters
Potential benefit: If successful, this study could provide a new treatment option for patients suffering from Meniere's disease.
How similar studies have gone: While there is limited research on this specific approach, the use of migraine medications for Meniere's disease is a novel concept that has not been extensively tested.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Patients with active or frequent Meniere's Disease. 2. Male or female between the ages of 25 to 85 years. 3. Subject must be compliant with the medication and attend study visits. 4. Must be able to read and write in the English language to provide consenting. Exclusion Criteria: 1. Pregnancy will result in automatic exclusion from the study. A urine pregnancy test to rule out pregnancy for all women who are of childbearing potential. 2. Subjects with history of surgery for Meniere's Disease. 3. Subject with history of an adverse reaction to medication being prescribed. 4. Subject suffers from a medical condition or has history that may be concerning to the investigator's clinical opinion. 5. Subjects with psychosis. 6. Subjects with neurological neoplasm. 7. All contraindications for the medications which prevent subjects from randomization will be considered as exclusion criteria.
Where it's running
-
University of California, Irvine Medical Center ENT Clinic (Pavilion 2)
Orange, California, United States Recruiting
Study contacts
- Principal investigator: Hamid Djalilian, MD — University of California, Irvine
- Study coordinator: Hamid R Djalilian
- Email: hdjalili@hs.uci.edu
- Phone: (800) 263-9547
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.